BeiGene Ltd
BGNE
ISIN null / Valor 30165310
BeiGene Ltd
UMushroom community rating:
About company
BeiGene Ltd is a publicly traded global oncology company with a market capitalization of approximately $23 billion and a global workforce of over 10,000 employees. The company has a presence in Asia, Australia, Europe, Latin America, and North America, with administrative offices in Basel, Beijing, and Cambridge, Mass. BeiGene is known for its growing portfolio of oncology treatments in various stages of development, with a focus on innovative and accessible medicines for cancer patients worldwide. The company collaborates with biopharmaceutical companies to develop and commercialize cancer therapies, and has a strong research team working on a broad pipeline of potential treatments. One of BeiGene's key products is BRUKINSA, a small molecule inhibitor of Bruton’s tyrosine kinase, approved for the treatment of various B-cell malignancies in 70 markets globally. Co-founded by John V. Oyler in 2010, BeiGene is dedicated to addressing a wide range of cancers and making a positive impact in the field of oncology.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
36089 M
Market cap (USD)
149,217
Daily traded volume (Shares)
185.01 / 179.74
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Christian Bircher
EQUITIES OF THE SAME SECTOR
